EASTGATE BIOTECH ANNOUNCES THAT IT HAS RECEIVED A SUBSTANTIAL ORDER FOR GLUCORA, ITS NATURAL GLUCOSE MANAGEMENT PRODUCT

West Caldwell, NJ and Toronto, May 2, 2016 (GlobeNewswire/-) EastGate Biotech Corp.

(PinkSheets: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has announced that it has received a large order for Glucora, its natural glucose management product.

The total order was for 15,000 bottles of 60 tablets/bottle for a total of over $270,000.00 USD.

The order was placed by Proactive Supply Chain Solutions Inc. (www.proactivegroup.ca) who also serves as a GMP fulfillment services center of varying industrial and commercial products. Proactive anticipates that it will have revolving purchase orders for Glucora.

“We have been very impressed by this innovative product”, says Sam Mancuso, CEO of Proactive. “We believe that Glucora has the opportunity to become an important player in glocose management market”. “I am most grateful to the EastGate team who provided technical support, training and marketing directions to support our ongoing relationship”.

Glucora is a soft capsule product that provides support for healthy glucose metabolism. Glucora contains natural ingredients in a highly efficient self-nanoemulsifying capsulation.

Additional information on the product can be found at www.nano-essentials.com.

“We are pleased that we have received our first material order for Glucora” says Anna

Gluskin, EastGate Biotech’s CEO. “We believe that Glucora is a product with mass market

appeal and will play a key role in the company’s diabetes franchise”.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference

in this news release constitute "forward-looking information" or "forward-looking statements"

within the meaning of certain securities laws, including the provisions for "safe harbour" under

the United States Private Securities Litigation Reform Act of 1995 and are based on

expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates",

"forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential",

"projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar

such words and phrases or statements that certain actions, events or results "may", "could",

"would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be

achieved" and similar expressions identify forward-looking statements. Forward-looking

statements are necessarily based upon a number of estimates and assumptions that are

inherently subject to significant business, economic and competitive risks, uncertainties and

contingencies. The risks, estimates, models and assumptions contained or incorporated by

reference in this release, include those identified from time to time in the reports filed by

EastGate with the SEC, which should be considered together with any forward-looking

statement. EastGate undertakes no obligation to update publicly any forward-looking

statements, whether as a result of new information, future events or otherwise.

CONTACT:  Rose Perri 1-647- 692-0652

Email:  information@eastgatepharmaceuticals.com

Website: www.EastGateBiotech.com